Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Boston Scientific entered this episode with the profile of a company that, on paper, still looked operationally strong.</li><li>In its latest quarterly update, management pointed to more than $20 billion in annual sales, mid-teens organic growth in 2025, double-digit adjusted EPS growth, and continued momentum in two of its most important franchises: electrophysiology and WATCHMAN.</li><li>Yet the stock fell sharply after investors zeroed in on one part of the CHAMPION trial data for WATCHMAN FLX: a 3.2% ischemic stroke rate in the device arm versus 2.0% for blood thinners.</li></ul>

Boston Scientific entered this episode with the profile of a company that, on paper, still looked operationally strong.In its latest quarterly update, management pointed to more than $20 billion in annual sales, mid-teens organic growth in 2025, double-digit adjusted EPS growth, and continued momentum in two of its most important franchises: electrophysiology and WATCHMAN.Yet the stock fell sharply after investors zeroed in on one part of the CHAMPION trial data for WATCHMAN FLX: a 3.2% ischemic stroke rate in the device arm versus 2.0% for blood thinners.

Boston Scientific Just Lost Billions Over One Tiny Number—Here’s What Really Happened!

<ul><li>Boston Scientific Corporation reported strong financial and operational results for the full year 2025, with total company sales exceeding $20 billion and organic revenue growth of 15.8%, surpassing initial guidance.</li><li>The company demonstrated broad-based growth across multiple business segments, including electrophysiology (EP), WATCHMAN, interventional oncology (IO), endoscopy (endo), and interventional cardiology therapies (ICTx).</li><li>Adjusted earnings per share (EPS) rose 22% to $3.06, also above projections, alongside a 100 basis point expansion in adjusted operating margins to 28%.</li></ul>

Boston Scientific Corporation reported strong financial and operational results for the full year 2025, with total company sales exceeding $20 billion and organic revenue growth of 15.8%, surpassing initial guidance.The company demonstrated broad-based growth across multiple business segments, including electrophysiology (EP), WATCHMAN, interventional oncology (IO), endoscopy (endo), and interventional cardiology therapies (ICTx).Adjusted earnings per share (EPS) rose 22% to $3.06, also above projections, alongside a 100 basis point expansion in adjusted operating margins to 28%.

Boston Scientific: Is Its Dominance In Pulsed Field Ablation About To Extend Even Further?

<ul><li>If you're wondering what Boston Scientific has been up to lately, buckle up.</li><li>On January 15, the medtech heavyweight announced it would acquire Penumbra for a staggering $15 billion in a cash-and-stock deal, offering $374 per share.</li><li>That represents a 19% premium over Penumbra's last close.</li></ul>

If you're wondering what Boston Scientific has been up to lately, buckle up.On January 15, the medtech heavyweight announced it would acquire Penumbra for a staggering $15 billion in a cash-and-stock deal, offering $374 per share.That represents a 19% premium over Penumbra's last close.

Boston Scientific Is Buying Penumbra—But the Real Story Is What Comes Next!

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Sahajanand Medical Technologies / Equity Bottom-Up

Sahajanand Medical Technologies (2585275D IN)

<ul>
<li>SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.</li>
<li>FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. </li>
<li>SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.</li>
</ul>


SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.
FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. 
SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.


Sahajanand Medical Technologies IPO: Global Stent Franchise, Emerging Structural Heart Opportunity

<ul><li>Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment, particularly in Electrophysiology (EP) and the WATCHMAN product line.</li><li>The company's operational sales ascended by 19%, with organic sales rising by 15%, both exceeding forecasted ranges.</li><li>This robust performance underscores Boston Scientific's strategic focus and execution prowess.</li></ul>

Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment, particularly in Electrophysiology (EP) and the WATCHMAN product line.The company's operational sales ascended by 19%, with organic sales rising by 15%, both exceeding forecasted ranges.This robust performance underscores Boston Scientific's strategic focus and execution prowess.

Boston Scientific: Inside China’s Explosive MedTech Boom!

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Boston Scientific Just Lost Billions Over One Tiny Number—Here’s What Really Happened!

Boston Scientific entered this episode with the profile of a company that, on paper, still looked operationally strong. In its latest quarterly...

Baptista Research

Boston Scientific: Is Its Dominance In Pulsed Field Ablation About To Extend Even Further?

Boston Scientific Corporation reported strong financial and operational results for the full year 2025, with total company sales exceeding $20...

Baptista Research

Boston Scientific Is Buying Penumbra—But the Real Story Is What Comes Next!

If you're wondering what Boston Scientific has been up to lately, buckle up. On January 15, the medtech heavyweight announced it would acquire...

Baptista Research

Sahajanand Medical Technologies IPO: Global Stent Franchise, Emerging Structural Heart Opportunity

Sahajanand Medical Technologies’ profits surged 175% in FY26, but rising debt and modest returns raise questions. Can its global medical-device...

Sudarshan Bhandari

Boston Scientific: Inside China’s Explosive MedTech Boom!

Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)